Bechtel Medical Wound VOX Receives FDA 510(k) Clearance: The First Cleared System Combining Negative Pressure and Topical Oxygen Therapy, With a Limited Release in December
Phoenixville, Pennsylvania — Bechtel Medical announced on November 10 that its flagship product, Wound VOX, has received 510(k) clearance from the U.S. Food and Drug Administration. The company describes it as the first 510(k)-cleared system combining negative pressure wound therapy and topical oxygen therapy in a single platform.
The system incorporates three modes of operation: continuous negative pressure, intermittent negative pressure, and intermittent negative pressure with adjunctive topical oxygen therapy. The company says integrating the two capabilities into one platform may reduce the operational complexity of deploying separate wound care technologies.
On independent research, a 2025 systematic review and meta-analysis in Advances in Wound Care evaluated 11 randomized controlled trials and reported higher complete wound healing rates and lower rates of bacterial positivity with combination treatment compared with negative pressure therapy alone. The company states plainly that those findings concern the treatment approaches studied and were not generated from clinical studies of Wound VOX itself.
Founder and CEO John Gvodas said the system was designed to simplify delivery of advanced wound care. The company plans a limited commercial release in December 2026. This report covers the clearance facts only and offers no individual treatment advice.
Source: 美通社
Published by GSM · USA (original Chinese edition)
Photo: 食品药品监督固定图库（GSM asset-packs）
CDC Updates Measles Data on November 6: 5,182 Confirmed Cases in 2026 as of November 5, With 43 New Outbreaks and 96 Percent of Cases Outbreak Associated2026-11-10
bioMérieux VITEK PRO System for Microbial Identification and Susceptibility Testing Cleared by the FDA: U.S. Launch Planned From the First Quarter of 2027, Replacing VITEK 2 and XL2026-11-10